the glucagon thing finally clicked for me and I want to write it down
Thinking out loud about this: the glucagon thing finally clicked for me and I want to write it down.
Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.
Kept a log specifically because there is so little published. It is one person and it is not data.
The thing that surprised me was how much of the discussion here is inference rather than measurement.
Please do not ask me what dose you should be on. I genuinely do not know and neither does anyone else here.
best — the order this archive was captured in
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part
The muscle cramps profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
small trial, big effect, wide error bars
phase 2 data only, and people quote it like it is a label
Sent a vial to Janoshik out of curiosity. Result was 98.8% against a claimed 98.5%, which is the first independent number I had seen for this compound anywhere.
Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.
Small fix — three receptors, not two.
nadia_norgaard is right about the escalation being the variable. It explains most of the difficult reports here.
Correcting my own comment above: that figure was the 36-week interim, not the 48-week endpoint.
the glucagon component is why the metabolic story reads differently
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
heart rate is the thing people report watching
heart rate is the thing people report watching
Agreed, and the glucagon arm is exactly why the comparison threads do not work.
What is the source for that figure — the published paper or a summary of it?
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
dose escalation in the trials was slow for a reason
- 1The phase 2 readout ran to 48 weeks in a few hundred participants with a…7 comments in this branch · started by u/customs_seizure_sid
- 2Increases in heart rate have been reported across this receptor class. The…6 comments in this branch · started by u/cold_chromatogram_only